Procainamide

Overview

Procainamide (PCA) is a medication of the antiarrhythmic class used for the treatment of cardiac arrhythmias. It is a sodium channel blocker of cardiomyocytes; thus it is classified by the Vaughan Williams classification system as class Ia. In addition to blocking the INa current, it inhibits the IKr rectifier K+ current. Procainamide is also known to induce a voltage-dependent open channel block on the batrachotoxin (BTX)-activated sodium channels in cardiomyocytes.[1][2] WP

Uses, dosage and effects

Medical

Procainamide is used for treating ventricular arrhythmias: ventricular ectopy and tachycardia and supraventricular arrhythmias: atrial fibrillation, and re-entrant and automatic supraventricular tachycardia. For example, it can be used to convert new-onset atrial fibrillation, and although was initially thought to be suboptimal for this purpose, a growing body of literature is amounting in support for this exact cause.[3][4][5] WP

It is administered by mouth, by intramuscular injection, or intravenously.[6][7] WP

Others

It has also been used as a chromatography resin because it somewhat binds protein.[8–11] WP

Risks and side effects

Side effects

There are many side effects following the induction of procainamide. These adverse effects are ventricular dysrhythmia, bradycardia, hypotension and shock. The adverse effects occur even more often if the daily doses are increased. Procainamide may also lead to drug fever and other allergic responses. There is also a chance that drug-induced lupus erythematosus occurs, which at the same time leads to arthralgia, myalgia and pleurisy. Most of these side effects may occur due to the acetylation of procainamide.[12] WP

Toxicity

There is a close line between the plasma concentrations of the therapeutic and toxic effect, therefore a high risk for toxicity. Many symptoms resemble systemic lupus erythematosus because procainamide reactivates hydroxylamine and nitroso metabolites, which bind to histone proteins and are toxic to lymphocytes. The hydroxylamine and nitroso metabolites are also toxic to bone marrow cells and can cause agranulocytosis. These metabolites are formed due to the activation of polymorphonuclear leukocytes. These leukocytes release myeloperoxidase and hydrogen peroxide, which oxidize the primary aromatic amine of procainamide to form procainamide hydroxylamine. The release of hydrogen peroxide is also called a respiratory burst, which occurs for procainamide in monocytes but not in lymphocytes. Furthermore, the metabolites can be formed by activated neutrophils. These metabolites could then bind to their cell membranes and cause a release of autoantibodies which would react with the neutrophils. Procainamide hydroxylamine has more cytotoxicity by hindering the response of lymphocytes to T-cell and B-cell mitogens. Hydroxylamine can also generate methemoglobin, a protein that could hinder further oxygen exchange.[12][13][14] WP

It was also detected that the antiarrhythmic drug procainamide interferes with pacemakers. A toxic level of procainamide leads to decrease in ventricular conduction velocity and increase of the ventricular refractory period. This results in a disturbance in the artificial membrane potential and leads to a supraventricular tachycardia which induces failure of the pacemaker and death. Thus, it prolongs QT interval of action potential and increases the risk of torsade de pointes.[1][15] WP

Procainamide could initiate leukopenia and/or agranulocytosis, which are serious hematologic disorders, and is also known for causing gastrointestinal disturbances and aggravating pre-existing abnormalities in impulse initiation and propagation.[3] WP

Pharmacology

Mechanism of action

Procainamide works as an anti-arrhythmic agent and is used to treat cardiac arrhythmia. It induces rapid block of the batrachotoxin (BTX)-activated sodium channels of the heart muscle and acts as antagonist to long-gating closures. The block is voltage-dependent and can occur from both sides; either from the intracellular or the extracellular side. Blocking from the extracellular side is weaker than from the intracellular side because it occurs via the hydrophobic pathway. Procainamide is present in charged form and probably requires a direct hydrophobic access to the binding site for blocking of the channel. Furthermore, blocking of the channel shows a decreased voltage sensitivity, which may result from the loss of voltage dependence of the blocking rate. Due to its charged and hydrophilic form, procainamide has its effect from the internal side, where it causes blockage of voltage-dependent, open channels. With increasing concentration of procainamide, the frequency of long blockage becomes less without the duration of blockage being affected. The rate of fast blocking is determined by the membrane depolarization. Membrane depolarization leads to increased blocking and decreased unblocking of the channels. Procainamide slows the conduction velocity and increases the refractory period, such that the maximal rate of depolarization is reduced. It is also said to be a selective muscarinic acetylcholine M₃ receptor antagonist.[2][16] WP

Metabolism

Procainamide is metabolized via different pathways. The most common one is the acetylation of procainamide to the less-toxic N-acetylprocainamide. The rate of acetylation is genetically determined. There are two phenotypes that result from the acetylation process, namely the slow and rapid acetylator. Procainamide can also be oxidized by the cytochrome P-450 to a reactive oxide metabolite. But it seems that acetylation of the nitrogen group of procainamide decrease the amount of the chemical that would be available for the oxidative route. Other metabolites of procainamide include desethyl-N-acetylprocainamide, desethylprocainamide, p-aminobenzoic acid, which are excreted via the urine. N-acetyl-4-aminobenzoic acid as well as N-acetyl-3-hydroxyprocainamide, N-acetylprocainamide-N-oxide and N-acetyl-4-aminohippuric acid are also metabolites of procainamide.[17][18] WP

History

History

Procainamide was approved by the US FDA on June 2, 1950, under the brand name "Pronestyl". It was launched by Bristol-Myers Squibb in 1951. Due to the loss of Indonesia in World War II, the source for cinchona alkaloids, a precursor of quinidine, was reduced. This led to research for a new antiarrhythmic drug. As a result, procaine was discovered, which has similar cardiac effects as quinidine. In 1936 it was found by Mautz that by applying it directly on the myocardium, the ventricular threshold for electrical stimulation was elevated. This mechanism is responsible for the antiarrhythmic effect. However, due to the short duration of action, caused by rapid enzymatic hydrolysis, its therapeutic applications were limited. In addition, procaine also caused tremors and respiratory depression. All these adverse features stimulated the search for an alternative to procaine. Studies were done on various congeners and metabolites and this ultimately led to the discovery of procainamide by Mark et al. It was found that procainamide was effective for treating ventricular arrhythmias, but it had the same toxicity profile as quinidine, and it could cause systemic lupus erythematosus-like syndrome. These negative characteristics slowed the search for new antiarrhythmics based on the chemical structure of procainamide. In 1970 only five drugs were reported. These were the cardiac glycosides, quinidine, propranolol, lidocaine and diphenylhydantoin. In January 1996, extended release procainamide hydrochloride (Procanbid extended-release tablets) was approved by the FDA.[19–24] WP

Chemistry

Formula

C13H21N3O PC

CAS number

51-06-9 PC

Molar mass (g/mol)

235.33 PC

IUPAC name (computed by PubChem)

4-amino-N-[2-(diethylamino)ethyl]benzamide PC

SMILES

CCN(CC)CCNC(=O)C1=CC=C(C=C1)N PC

InChIKey

REQCZEXYDRLIBE-UHFFFAOYSA-N PC

PubChem CID

4913

IUPAC name

4-amino-N-(2-diethylaminoethyl) benzamide WP

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Journal / agency Osadchii OE. Procainamide and lidocaine produce dissimilar changes in ventricular repolarization and arrhythmogenicity in guinea-pig. Fundamental & Clinical Pharmacology. August 2014. doi:10.1111/fcp.12046 · PMID 23952942
2. Journal / agency Zamponi GW, Sui X, Codding PW, French RJ. Dual actions of procainamide on batrachotoxin-activated sodium channels: open channel block and prevention of inactivation. Biophysical Journal. December 1993. doi:10.1016/S0006-3495(93)81291-8 · PMID 8312472 · PMC1225974
3. Other Drug Treatment of Cardiac Arrhythmias. 1983
4. Journal / agency Stiell IG, Sivilotti ML, Taljaard M, Birnie D, Vadeboncoeur A, Hohl CM, McRae AD, Rowe BH, Brison RJ, Thiruganasambandamoorthy V, Macle L, Borgundvaag B, Morris J, Mercier E, Clement CM, Brinkhurst J, Sheehan C, Brown E, Nemnom MJ, Wells GA, Perry JJ. Electrical versus pharmacological cardioversion for emergency department patients with acute atrial fibrillation (RAFF2): a partial factorial randomised trial. Lancet. February 2020. doi:10.1016/S0140-6736(19)32994-0 · PMID 32007169
5. Journal / agency Fenster PE, Comess KA, Marsh R, Katzenberg C, Hager WD. Conversion of atrial fibrillation to sinus rhythm by acute intravenous procainamide infusion. American Heart Journal. September 1983. doi:10.1016/0002-8703(83)90692-0 · PMID 6881022
6. Journal / agency Koch-Weser J, Klein SW. Procainamide dosage schedules, plasma concentrations, and clinical effects. JAMA. March 1971. doi:10.1001/jama.1971.03180220036006 · PMID 5107621
7. Other Cardiovascular Therapeutics: A companion to Braunwald's heart disease. 2013
8. Other Procainamide Sepharose 4 Fast Flow
9. Journal / agency De la Hoz D, Doctor BP, Ralston JS, Rush RS, Wolfe AD. A simplified procedure for the purification of large quantities of fetal bovine serum acetylcholinesterase. Life Sciences. July 1986. doi:10.1016/0024-3205(86)90530-8 · PMID 3736320
10. Journal / agency Ralston JS, Main AR, Kilpatrick BF, Chasson AL. Use of procainamide gels in the purification of human and horse serum cholinesterases. The Biochemical Journal. April 1983. doi:10.1042/bj2110243 · PMID 6870822 · PMC1154348
11. Journal / agency Saxena A, Luo C, Doctor BP. Developing procedures for the large-scale purification of human serum butyrylcholinesterase. Protein Expression and Purification. October 2008. doi:10.1016/j.pep.2008.05.021 · PMID 18602477
12. Journal / agency Lawson DH, Jick H. Adverse reactions to procainamide. British Journal of Clinical Pharmacology. October 1977. doi:10.1111/j.1365-2125.1977.tb00777.x · PMID 911600 · PMC1429167
13. Journal / agency Uetrecht J, Zahid N, Rubin R. Metabolism of procainamide to a hydroxylamine by human neutrophils and mononuclear leukocytes. Chemical Research in Toxicology. January 1988. doi:10.1021/tx00001a013 · PMID 2979715
14. Journal / agency Roberts SM, Adams LE, Donovan-Brand R, Budinsky R, Skoulis NP, Zimmer H, Hess EV. Procainamide hydroxylamine lymphocyte toxicity--I. Evidence for participation by hemoglobin. International Journal of Immunopharmacology. 1989. doi:10.1016/0192-0561(89)90089-1 · PMID 2476407
15. Journal / agency Gay RJ, Brown DF. Pacemaker failure due to procainamide toxicity. The American Journal of Cardiology. November 1974. doi:10.1016/0002-9149(74)90164-7 · PMID 4422040
16. Journal / agency Lavrador M, Cabral AC, Veríssimo MT, Fernandez-Llimos F, Figueiredo IV, Castel-Branco MM. A Universal Pharmacological-Based List of Drugs with Anticholinergic Activity. Pharmaceutics. January 2023. doi:10.3390/pharmaceutics15010230 · PMID 36678858 · PMC9863833
17. Journal / agency Roden DM, Reele SB, Higgins SB, Wilkinson GR, Smith RF, Oates JA, Woosley RL. Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: comparison with procainamide. The American Journal of Cardiology. September 1980. doi:10.1016/0002-9149(80)90016-8 · PMID 6158263
18. Journal / agency Uetrecht JP, Freeman RW, Woosley RL. The implications of procainamide metabolism to its induction of lupus. Arthritis and Rheumatism. August 1981. doi:10.1002/art.1780240803 · PMID 6169352
19. Journal / agency US Food and Drug Administration. Drugs at FDA: FDA Approved Drug Products
20. Journal / agency Hollman A. Procaine and procainamide. British Heart Journal. February 1992. doi:10.1136/hrt.67.2.143 · PMID 18610401 · PMC1024743
21. Journal / agency Walker MJ. Antiarrhythmic drug research. British Journal of Pharmacology. January 2006. doi:10.1038/sj.bjp.0706500 · PMID 16402108 · PMC1760742
22. Other Moe GK, Abildskov A. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 1965
23. Other History of Disorders of Cardiac Rhythm. 2002
24. Journal / agency Mishina E, Marroum P. Center for Drug Evaluation and Research Approval Package For: Application Number NDA 20-545/S007. 2002

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0), PubChem (public domain). Each value links to the exact revision it came from.